127 results
424B3
KZIA
Kazia Therapeutics Limited
19 Apr 24
Prospectus supplement
4:30pm
to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of Warrant ADSs, all of which taxes and expenses shall … , the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all fees charged by the ADS Depositary
6-K
EX-4.1
KZIA
Kazia Therapeutics Limited
19 Apr 24
Current report (foreign)
4:26pm
to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of Warrant ADSs, all of which taxes and expenses shall … , the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all fees charged by the ADS Depositary
6-K
EX-10.1
KZIA
Kazia Therapeutics Limited
19 Apr 24
Current report (foreign)
4:26pm
contemplated by this Agreement with its own legal counsel and investment and tax advisors. The Investor is relying solely on such counsel and advisors … and not on any statements or representations of the Company or any of its representatives or agents for legal, tax or investment advice with respect
424B3
KZIA
Kazia Therapeutics Limited
27 Mar 24
Prospectus supplement
8:37am
providing for income tax amounted to $8,823,513 (31 December 2022: $13,586,027).
The attached financial statements detail the performance and financial …
Fair value gain on financial liabilities
Loss on revaluation of contingent consideration
Loss before income tax benefit
Income tax benefit
Loss after
6-K
EX-99.1
KZIA
Kazia Therapeutics Limited
27 Mar 24
Current report (foreign)
8:26am
for the Consolidated entity after providing for income tax amounted to $8,823,513 (31 December 2022: $13,586,027).
The attached financial statements detail … and administrative expense
Fair value gain on financial liabilities
Loss on revaluation of contingent consideration
Loss before income tax benefit
Income
424B3
6e3x984o
5 Feb 24
Prospectus supplement
4:19pm
F-1
zinrlb6vpk9eo3th
31 Jan 24
Registration statement (foreign)
12:00am
F-1
EX-3.1
be1d 6xw8
31 Jan 24
Registration statement (foreign)
12:00am
6-K
EX-4.2
45g8bofj552lj8hon3hu
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
6-K
EX-4.3
ewn4qtlxd0
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
6-K
EX-4.1
s7olmsr dadzmwg4lcoj
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
6-K
EX-10.1
31403u 91
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
424B5
5k7 ib6adoyk5fqa7tx
4 Dec 23
Prospectus supplement for primary offering
4:05pm
6-K
EX-99.2
4h1ru10iueyvx nw5brc
13 Oct 23
Current report (foreign)
4:08pm
6-K
EX-99.2
ayv eqv11d20ypbkyl8
5 Sep 23
Current report (foreign)
7:02am
6-K
EX-99.1
vaetg
5 Sep 23
Current report (foreign)
7:02am
6-K
EX-99.2
oki3nah2xzkdmr0b2w8
1 Sep 22
Current report (foreign)
4:07pm